PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
11.15%
Revenue growth above 1.5x MRVL's 4.29%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
8.67%
Gross profit growth above 1.5x MRVL's 3.82%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
-18.95%
Negative EBIT growth while MRVL is at 8.09%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-14.93%
Negative operating income growth while MRVL is at 15.99%. Joel Greenblatt would press for urgent turnaround measures.
-47.61%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-48.68%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-47.22%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
0.47%
Slight or no buybacks while MRVL is reducing shares. John Neff might see a missed opportunity if the company’s stock is cheap.
-4.07%
Reduced diluted shares while MRVL is at 1.17%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
2.45%
Maintaining or increasing dividends while MRVL cut them. John Neff might see a strong edge in shareholder returns.
-23.75%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-222.99%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
42.96%
10Y revenue/share CAGR at 75-90% of MRVL's 56.20%. Bill Ackman would press for new markets or product lines to narrow the gap.
-19.24%
Negative 5Y CAGR while MRVL stands at 109.65%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
13.52%
3Y revenue/share CAGR at 50-75% of MRVL's 25.49%. Martin Whitman would question if the firm lags behind competitor innovations.
2418.16%
10Y OCF/share CAGR above 1.5x MRVL's 237.57%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
-16.24%
Negative 5Y OCF/share CAGR while MRVL is at 45.44%. Joel Greenblatt would question the firm’s operational model or cost structure.
-19.88%
Negative 3Y OCF/share CAGR while MRVL stands at 63.72%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
7472.52%
Net income/share CAGR above 1.5x MRVL's 653.69% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
105.66%
Below 50% of MRVL's 220.76%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
-64.38%
Negative 3Y CAGR while MRVL is 202.86%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
287.85%
10Y equity/share CAGR above 1.5x MRVL's 54.87%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
182.94%
5Y equity/share CAGR above 1.5x MRVL's 19.67%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
76.79%
Positive short-term equity growth while MRVL is negative. John Neff sees a strong advantage in near-term net worth buildup.
15.66%
10Y dividend/share CAGR above 1.5x MRVL's 0.04%. David Dodd checks if the firm's robust cash flows justify outpacing the competitor's increases.
-4.26%
Both lowered dividends mid-term. Martin Whitman might suspect broad sector constraints or strategic shifts from dividends.
-1.77%
Both firms reduced dividends recently. Martin Whitman suspects broader macro or industry issues forcing cost and payout cuts.
12.58%
AR growth well above MRVL's 11.24%. Michael Burry fears inflated revenue or higher default risk in the near future.
10.11%
Inventory growth well above MRVL's 4.05%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
-6.23%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-2.27%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
4.89%
Debt growth far above MRVL's 3.89%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
33.25%
R&D growth drastically higher vs. MRVL's 1.74%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
13.25%
We expand SG&A while MRVL cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.